Theravance Corp (TBPH) - Long-Term Debt to Capital Coefficient

This daily price chart for Theravance Biopharma (TBPH) demonstrates metrics where the value is 0.21. Theravance Biopharma (TBPH) maintains resilience in the pulmonary sector, relying on complex formulas to protect against generics. The business generates revenue through royalties from partner drug sales, which minimizes costs. Simultaneously, the company is implementing precision targeting methods for specific organs, reducing the toxicity of chronic disease therapies.

Assessing the reliability of equity assets begins with analyzing the stability of the financing structure relative to long-term liabilities. The ratio of loans with a maturity of over one year to total equity determines the degree of financial autonomy for Theravance Biopharma (TBPH), which is critical for capital-intensive developments in internal organ therapy, and is clearly reflected in the dynamics of the long-term debt-to-equity ratio.